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Mycophenolate mofetil (MMF) is frequently used in hematopoietic cell transplantation (HCT) for graft-versus-
host disease (GVHD) prophylaxis and to facilitate engraftment. We previously reported that a higher level of
mycophenolic acid can be achieved with an MMF dose of 3 g/day than with 2 g/day. Here, we retrospectively
compared clinical outcomes of reduced-intensity conditioning (RIC) double umbilical cord blood (dUCB) HCT
recipients receiving cyclosporine A with MMF 2 g (n ¼ 93) versus 3 g (n ¼ 175) daily. Multiple regression
analysis adjusted for antithymocyte globulin in the conditioning revealed that MMF 3 g/day led to a 49%
relative risk (RR) reduction in grade II to IV acute GVHD rate (RR, .51; 95% conﬁdence interval, .36 to .72;
P < .01). However, the higher MMF dose was not protective for chronic GVHD. Additionally, MMF dose was
not an independent predictor of neutrophil engraftment or treatment-related mortality at 6 months or 2-year
post-transplantation disease relapse, disease-free survival, or overall survival. Higher MMF dose did not in-
crease risk of infectious complications, and infection-related mortality was similar for both MMF doses. Our
data indicate that MMF 3 g/day reduces the risk of acute GVHD without affecting other clinical outcomes and
should be used for GVHD prophylaxis after RIC dUCB transplantation.
 2015 American Society for Blood and Marrow Transplantation.INTRODUCTION
Double umbilical cord blood (dUCB) hematopoietic cell
transplantation (HCT) in the myeloablative and reduced-
intensity conditioning (RIC) settings has extended the use
of umbilical cord blood (UCB) grafts to adults and large ad-
olescents who would not have a suitable single-unit umbil-
ical cord blood (UCB) graft [1-3]. Although engraftment
remains delayed and less complete among UCB recipients
than recipients from adult donors [4], it is similar among
recipients of single UCB and dUCB grafts [5,6]. However, we
found that the risk of grade II to IV but not grade III and IV
acute graft-versus-host disease (GVHD) is higher among
dUCB recipients than single UCB recipients [7]. We andedgments on page 932
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ty for Blood and Marrow Transplantation.others use mycophenolate mofetil (MMF) as part of the im-
mune suppression regimen in HCT [2,3,7-12]. Our group
previously demonstrated that a low unbound mycophenolic
acid (MPA), which is the active metabolite of MMF, area
under the curve (AUC) is associated with higher rates of graft
failure and grade II to IV acute GVHD in RIC UCB, matched
sibling, and adult unrelated donor transplantation [13]. In
addition, a report of adult unrelated donor HCT using a ﬂu-
darabine/total body irradiationebased nonmyeloablative
conditioning regimen suggests superior engraftment with a
higher MPA AUC [9]. On the basis of these observations, we
modiﬁed our UCB HCT protocols and increased the MMF
dose from 2 g to 3 g per day. In pharmacokinetic studies, we
showed that MMF 3 g/day, administered either as 1.5 g twice
daily or 1 g thrice daily, achieved the unbound 24-hour cu-
mulative MPA target AUC (.600 mg*hour/mL) in over 87% of
patients, in contrast to MMF 2 g/day (1 g twice daily) where
less than one half of patients achieved the target AUC [13,14].
Here, we report the outcomes associated with use of MMF 3
g/day in dUCB HCT.
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Patients
Eligible patients included adults with hematologic malignancies who
received a RIC dUCB HCT at the University of Minnesota between 2000
and 2012. Our group previously reported 110 of these patients [1,3]. All
patients were treated in clinical protocols approved by the institutional
review board of the University of Minnesota, and either the patient or
his/her legal guardian provided written informed consent in accor-
dance with the Declaration of Helsinki prior of proceeding with
transplantation.
Immune-Suppression Regimen
All patients received immunosuppressive therapy consisting of MMF
and cyclosporine A (CSA). MMF was administered from days 3 to þ30 or 7
days after neutrophil engraftment, whichever was later, in the absence of
acute GVHD. MMF was administered 2 g/day twice daily (2000 to 2005) or 3
g/day (2006 to 2012) in 2 or 3 divided doses. Although research-related
MMF/MPA pharmacokinetics data were obtained in a subset of patients, as
previously reported [13,14], MPA AUC was not used to personalize MMF
dosing. CSAwas administered from day3 to dayþ180 with a target trough
level between 200 and 400 ng/mL and, in the absence of GVHD, tapered by
day þ180 [15].
Treatment
UCB graft selection criteria, conditioning regimens, and supportive
care have been previously reported [1-3]. In summary, a minimum of 4 of 6
HLA loci were matched to the patient; HLA-A and HLA-B were matched at
the antigen level and HLA-DRB1 was matched at the allele level [3]. The 2
UCB units were HLA matched to each other at a minimum of 4 of 6 HLA loci
but not necessarily at the same loci as the patient. Target selection for
cryopreserved total nucleated cell dose for the 2 UCB units ranged from 2
to 3.5  107 total nucleated cells/kg thereafter. The nonmyeloablative
regimen consisted of ﬂudarabine 200 mg/m2, cyclophosphamide 50 mg/
kg, and a single fraction of total body irradiation 200 cGy [3]. Equine
antithymocyte globulin (ATG; 90 mg/kg) was included in the preparative
regimen for those patients who received no immunosuppressive multi-
agent chemotherapy within the prior 3 months or with no prior autolo-
gous transplantation; since 2005, if autologous transplantation within
12 months of the allograft [1,3]. Anti-infectious prophylaxis included ﬂu-
oroquinolone for bacterial infections, either ﬂuconazole or voriconazole
for fungal infections, acyclovir for viral infections, and trimethoprim-
sulfamethoxazole or pentamidine for Pneumocystis jiroveci infection [3].
Granulocyteecolony stimulating factor (5 mg/kg/day) was administered to
all patients from day 0 or þ1 until absolute neutrophil count > 2.5  109/L
for 2 consecutive days [1,3].
Deﬁnitions and Endpoints
Data on baseline patient and disease characteristics, transplantation-
related factors, and clinical outcome measures were prospectively
collected and recorded by the University of Minnesota blood and marrow
transplant department. Study endpoints included cumulative incidences of
neutrophil engraftment by dayþ42 (deﬁned as absolute neutrophil count >
.5  109/L for 3 consecutive days), nonrelapse mortality (NRM) at 6 months,
and relapse/progression at 2 years, as well as the probabilities of disease-
free survival (DFS; deﬁned as being alive and with no evidence of disease
relapse/progression), and overall survival (OS). Additional endpoints
included the cumulative incidences of acute GVHD at day þ100 and chronic
GVHD at þ2 years. As our study included patients treated before the
adoption of the consensus chronic GVHD criteria [16], acute GVHD was
deﬁned as any signs or symptoms of GVHD occurring by dayþ100 according
to published criteria [17]. Chronic GVHD was deﬁned as any signs or
symptoms of GVHD occurring after day þ100. Frequency and density of
infections was studied within speciﬁc post-transplantation time intervals of
days 0 to þ45, days þ46 to þ180, and days þ181 to þ365. The day of each
infectious episode was calculated from the day of transplantation (day 0).
Pathogenic organisms were categorized based on genus into bacterial,
fungal, or viral groups. Neutropenic fever events without identiﬁable in-
fectious source were not included. An infectious episode was deﬁned as any
infection requiring treatment that was identiﬁed by culture, cytology, his-
tology, antigenemia, or polymerase chain reaction (PCR). No microbiologic
conﬁrmation was required for documentation of dermatomal varicella-
zoster viral infectious episode. Human herpesvirus 6 PCR testing became
routinely available at our center in 2006; therefore, cases of Human
herpesvirus 6 infection were not included in this analysis to avoid con-
founding bias with MMF dosing. Cytology ﬁndings of unspeciated fungal
elements were acceptable for documentation of probable invasive fungal
infections if compatible with the clinical scenario. Speciﬁc time frames were
used to separate 1 infectious episode from another: 7 days was required forbacteria (except 31 days for Clostridium difﬁcile), 90 days for mold (14 days
for yeast), and 60 days for cytomegalovirus (CMV) and herpes simplex virus
(14 days for other viruses) [18]. On the basis of the affected site, infections
were categorized as blood stream, central nervous system, gastrointestinal,
intra-abdominal, urinary tract, upper respiratory tract, lower respiratory
tract, skin and soft tissue, and other infections or viral reactivation. Sex and
HLA matching between UCB and patient was studied considering the worst
matched of the 2 UCB units. Disease risk at the time of HCT was classiﬁed
into standard risk or high risk on the basis of the American Society for Blood
and Marrow Transplantation request for information 2006 risk scoring
schema (http://www.asbmt.org). Standard-risk disease included acute leu-
kemia in ﬁrst or second complete remission, chronic myeloid leukemia in
ﬁrst chronic phase, Hodgkin or non-Hodgkin lymphoma in complete or
partial chemotherapy-sensitive remission, chronic lymphocytic leukemia in
ﬁrst remission; all other disease states were determined to be high risk at
the time of transplantation. Patients were assessed for the HCT comorbidity
index (HCT-CI) as previously reported [19].
Statistical Analysis
Statistical comparisons for categorical factors were completed with the
chi-square test. Continuous factors across 2 MMF doses were compared by
the general Wilcoxon test for nonparametric data. Kaplan-Meier curves
were used to estimate the probability of DFS or OS using Greenwood’s
method to calculate the 95% conﬁdence intervals (CI) [20]. The log-rank test
was used to complete the comparisons. Cox regressionwas used to examine
the independent effect of MMF dose on DFS and OS through 2 years after
transplantation [21]. Factors considered in the regression models included
highest mismatch for HLA disparity considering the worst matched of the 2
UCB units (4/6 versus 5/6 versus 6/6), age (18 to 34 versus 35 to 59 versus
60þ), disease risk (standard versus high risk), gender (male versus female),
gender match (female donor to male recipient), Karnofsky performance
status at baseline (60% to 80% versus 90% to 100%), HCT-CI (0 versus 1 to 2
versus 3), and recipient CMV serostatus (positive versus negative). Anal-
ysis by MMF dose cohort was tested for any violations in the proportional
hazards assumption. Cumulative incidence treating nonevent deaths as a
competing risk was used to estimate the probability of neutrophil engraft-
ment, relapse, and acute and chronic GVHD. Cumulative incidence treating
relapse as a competing risk was used to estimate NRM [22]. Fine and Gray
regression analyses were used to look at the MMF dose cohort for the
endpoints of engraftment, relapse, NRM, and GVHD [23]. Backward selection
was used to build prognostic factor models for all endpoints considering a P
value of <.10. A P value of .05 was considered signiﬁcant for remaining in
the model; however, MMF dose was included in all models regardless of
signiﬁcance. The adjusted cumulative incidence curves were estimated for
acute GVHD based on risk factors signiﬁcant in the regression model [24,25].
Incorporating multiple infections per patient, the rates of infections were
estimated by the infection density per 1000 patient days. We used speciﬁc
post-transplantation time intervals (days 0 to 45, days 46 to 180, and days
181 to 365) to study the effect of MMF dose on frequency of bacterial, fungal,
and viral infections. Comparisons were completed with the Mantel-
Haenszel test for person-years data.
RESULTS
Patient Characteristics
We identiﬁed 268 patients with hematologic malig-
nancies who received RIC dUCB HCT at the University of
Minnesota between 2000 and 2012 (Table 1). Nearly twice as
many patients received MMF 3 g/day (n¼ 175) than received
MMF 2 g/day (n ¼ 93). Median age at transplantation was
53 years (range, 18 to 72). As deﬁned in this retrospective
study design, the year of transplantation variable was asso-
ciated with MMF dose. Patients receiving MMF 3 g/day
received a higher MMF dose per kilogram body weight and
better HLA-matched grafts, which is consistent with the
larger inventory of UCB units in recent years. Otherwise, the
2 groups were similar regarding patient and disease cha-
racteristics, proportion of CMV seropositivity, HCT-CI score,
use of ATG as part of the preparative regimen, and total
infused CD34þ cell dose.
Higher MMF Dose Reduces the Risk of Acute GVHD
After adjusting for use of ATG, the cumulative incidence of
grade II to IV acute GVHD by day þ100 was signiﬁcantly
lower in those receiving MMF 3 g/day (43% versus 63%,
Figure 1. Grade II to IV acute GVHD by MMF dose.
Figure 2. Organ involvement with grade II to IV acute GVHD.
Table 1
Patient Characteristics
Variable MMF 2 mg
n ¼ 93
MMF 3 mg
n ¼ 175
P Value*
Age, median
(range), yr
52 (21-69) 54 (18-72) .18
Male 58 (62) 105 (60) .71
Year of HCT <.001
2000-2005 92 (99) 4 (2)
2006-2012 1 (1) 171 (98)
HLA disparity
(worst match)
<.001
4/6 73 (78) 82 (47)
5/6 18 (19) 79 (45)
6/6 2 (2) 14 (8)
ATG in conditioning 29 (31) 57 (33) .82
Diagnosis .24
AML 31 (33) 73 (42)
MDS 11 (12) 31 (18)
CML 6 (7) 3 (2)
ALL 9 (10) 13 (7)
Lymphoma 25 (27) 42 (24)
CLL 6 (7) 7 (4)
Othery 5 (5) 6 (4)
Disease risk .23
Standard 39 (42) 87 (50)
High 54 (58) 88 (50)
HCT-CI .60
0 20 (22) 47 (27)
1-2 25 (27) 41 (23)
3 42 (45) 87 (50)
Missing 6 (7) 0
CMV seropositive 49 (53) 109 (62) .13
Total CD34, median
(range),  106/kg
.5 (.1-1.7) .5 (.1-3.5) .24
Weight, median
(range), kg
78.2 (52.7-134.0) 80.4 (43.7-142.3) .47
Body mass index,
median (range)
26.7 (19.6-39.6) 27.5 (17.2-45.0) .20
MMF (mg/kg),
median (range)
2.56 (1.49-3.80) 3.73 (2.11-6.86) <.01
First quartile (<2.7) 55 (59) 32 (18) <.01
Second quartile
(2.7-3.2)
29 (31) 32 (18)
Third quartile (3.2-3.9) 9 (10) 51 (29)
Fourth quartile (>3.9) 0 60 (34)
AML indicates acute myeloid leukemia; MDS, myelodysplastic syndrome;
CML, chronic myeloid leukemia; ALL, acute lymphoid leukemia; CLL, chronic
lymphoid leukemia.
Data presented are n (%) unless otherwise indicated.
* P value for between-treatment comparisons. Continuous variables were
analyzed by general Wilcoxon test. Categorical variables were analyzed by
chi-square.
y Other includes diagnoses of plasma cell disorders and biphenotypic
leukemia.
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trend towards being signiﬁcantly lower in those receiving 3
g/day (14% versus 23%; P ¼ .06). Among patients who
developed grade II to IV acute GVHD, the proportion of liver
involvement was signiﬁcantly higher in those receivingMMF
2 g/day (12% versus 34%, P < .01); however, other speciﬁc
organ or multiorgan involvement with acute GVHD was
similar for both MMF doses (Figure 2). In multivariable
analysis, after adjusting for ATG use in conditioning regimen,
MMF 3 g/day was associated with 49% relative risk (RR)
reduction in grade II to IV acute GVHD (RR, .51; 95% CI, .36 to
.72; P < .01) (Table 2).
The cumulative incidence of chronic GVHD was not
signiﬁcantly different between the MMF doses (20% versus
27%, P ¼ .17) (Table 3). In multivariable analysis, after
adjusting for gender and female donor use for male recipient,MMF dose had no signiﬁcant inﬂuence on chronic GVHD
(RR, .69 for MMF 3 g/day; 95% CI, .41 to 1.15; P ¼ .15).MMF Dose Does Not Inﬂuence Hematopoietic Recovery
The cumulative incidences of neutrophil recovery were
93% for MMF 3 g/day and 94% for MMF 2 g/day. Median time
to neutrophil engraftment was similar for both MMF doses
(14 days for 3 g/day and 12 days for 2 g/day; P ¼ .96)
(Figure 3). In univariable analysis, age and infused CD34 dose
were associated with neutrophil engraftment by day 42
(Table 3). In multivariable analysis, MMF dose was not an
independent predictor of neutrophil engraftment (MMF 3 g/
day, RR¼ .96; 95% CI, .71 to 1.28; P ¼ .76). However, age (60
years, RR, .69; 95% CI, .49 to .96; P ¼ .03) was associated with
poor engraftment whereas higher total infused CD34 dose
(3.5  107; RR, 1.40; 95% CI, 1.03 to 1.90; P ¼ .03) was
associated with more frequent engraftment. Cumulative in-
cidences of platelet recovery were 75% for MMF 3 g/day and
68% for MMF 2 g/day. Median time to platelet recovery was
similar for both MMF doses (48 days for MMF 3 g/day and 58
days for MMF 2 g/day; P¼ .16). However, a comorbidity score
of 3 was a predictor of poor platelet engraftment (RR, .67;
95% CI, .47 to .94; P¼ .02), whereas higher total infused CD34
dose (3.5  107; RR, 1.81; 95% CI, 1.29 to 2.55; P < .01) was
associated with more frequent engraftment.Higher MMF Dose Does Not Increase Risk of Infectious
Complications
Overall, there were 402 bacterial infection events. The
most commonly isolated bacterial pathogen was staphylo-
coccus (40%). Other bacterial pathogens isolated less
Table 2
Grade II to IV Acute GVHD by Day 100
Variable n Cumulative Incidence Multivariable
Estimate (%) 95% CI P Value RR 95% CI P Value
MMF <.01 <.01
2 g 93 63 52-75 1.0 .36-.72
3 g 175 43 35-51 .51
Age .01 e e e
18-34 years 26 46 26-66
35-59 years 176 57 49-65
60þ years 66 33 22-45
Gender .85 e e e
Male 163 50 42-59
Female 105 50 39-60
Year of HCT <.01 e e e
2000-2005 96 64 52-75
2006-2012 172 42 33-50
HLA disparity .89 e e e
4/6 155 49 41-57
5/6 97 52 41-62
6/6 16 50 24-76
Disease risk .65 e e e
Standard risk 126 49 40-59
High-risk 142 51 42-60
HCT-CI .82 e e e
0 67 54 41-67
1-2 66 50 37-63
3 129 47 37-56
Female donor to male recipient .94 e e e
Yes 141 50 41-59
No 127 50 40-59
CMV serostatus .78 e e e
Positive 110 51 41-61
Negative 158 49 41-58
ATG .06 .41-.88 .01
No 182 54 46-62 1.0
Yes 86 41 30-52 .60
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mycobacterium (4%), and others (total 20%). Fungal in-
fections were relatively rare (n ¼ 34). Aspergillosis was the
most frequent (38%) fungal infection, followed by candida
and other yeasts (29%), zygomycosis (21%), hyalohyphomy-
cosis (9%), and unspeciﬁed invasive fungal infections (3%).
Viral infectious events (n ¼ 313) included CMV (43%), BK
virus (13%), Epstein-Barr virus (9%), adenovirus (8%),
varicella-zoster viral (7%), herpes simplex virus (7%), and
others (13%). To assess the effect of MMF dosing on risk of
infection, we used the infection density function per 1000
patient days, which takes into account multiple infections in
an individual patient within speciﬁc post-transplantation
time intervals. MMF dose had no impact on bacterial in-
fections at early (days 0 to 45, 13.65 versus 18.40, P ¼ .05) or
late (days 181 to 365, .74 versus 1.49, P ¼ .03) post-
transplantation time periods. However, MMF 3 g/day was
associated with a lower density of bacterial infections (4.63
versus 9.44; P < .01) and total serious infections (all genus
types combined, 10.14 versus 15.63; P < .01) between post-
transplantation days 46 and 180 (Figure 4). In addition, the
infection density rates of both fungal and viral infections
were similar for both MMF doses at all post-transplantation
time intervals. Cumulative incidence of infection-related
death at 1 year was similar for both MMF doses (12% for 3
g/day versus 14% for 2 g/day; P ¼ .59).
Higher MMF Dose Does Not Inﬂuence Risk of Relapse or
Survival
The cumulative incidence of NRM at 6monthswas similar
for both MMF doses (14% for 3 g/day versus 15% for 2 g/day,P ¼ .74). In univariable analysis, high-risk disease resulted in
increased risk of NRM (Table 3). In multivariable analysis,
after adjusting for disease risk and ATG use in conditioning,
the higher MMF dose had no impact on NRM (RR, .93 for
MMF 3 g/day; 95% CI, .48 to 1.81; P ¼ .83). Similarly there
were no differences in relapse rates at 2 years by MMF dose
(43% for 3 g/day versus 40% for 2 g/day; P ¼ .78). In uni-
variable analysis, ATG use in conditioning was associated
with a decreased rate of relapse. In multivariable analysis,
after adjusting for use of ATG in the conditioning regimen,
therewas no association betweenMMF dose and relapse (RR,
1.14 for MMF 3 g/day; 95% CI, .77 to 1.69; P ¼ .52). The prob-
ability of DFS at 2 years was 37% for 3 g/day versus 40% for 2 g/
day (P ¼ .88). In univariate analysis, low (<3.5  107/kg)
CD34 cell dose was the only factor associated with inferior
DFS. In Cox regression analysis, low CD34 cell dose remained
predictive for treatment failure, but MMF 3 g/day dose had
no impact on it (RR, 1.05; 95% CI, .77 to 1.43; P¼ .74). Survival
of all patients at 2 years after transplantation was 61% for
MMF 3 g/day and 62% for MMF 2 g/day (P ¼ .85). In uni-
variable analysis, better survival was observed only among
patients receiving total  3.5  107/kg CD34 cell dose. In Cox
regression analysis, survival was not signiﬁcantly inﬂuenced
by total infused CD34 cell dose or MMF dose (RR, 1.03 for 3
gMMF; 95% CI, .72 to 1.47; P¼ .87). Primary causes of death at
2 years were similar for 3 g and 2 g MMF doses, with the
predominant causes of mortality being malignancy relapse
(65% versus 60%), followed by infection (16% versus 15%),
organ toxicity or failure (6% versus 8%), bleeding (1%
versus 4%), graft failure (1% versus 0%), and other causes (11%
versus 13%).
Table 3
Clinical Outcomes by MMF Dose
Variable n Univariable Multivariable
Estimate (%) 95% CI P Value RR 95% CI P Value
Neutrophil engraftment 1.0 .71-1.28
MMF .96 .96
2 g 93 94 91-97
3 g 175 93 88-98 .76
HLA disparity 89-97 .20
4/6 155 93 91-99 1.0
5/6 97 95 1.18 .89-1.57 .25
6/6 16 100 1.64 .91-2.97 .10
Age .02
<34 26 100 1.0
35-59 176 95 92-98 1.07 .80-1.43 .25
60þ 66 89 81-97 .69 .49-.96 .03
CD34 dose .02
<3.5  107 64 89 81-97 1.0
3.5  107 204 95 92-98 1.40 1.03-1.90 .03
Platelet engraftment (20K) .16
MMF
2 g 93 68 56-80 1.0
3 g 175 75 66-84 1.26 .93-1.70 .14
HLA disparity .03 e e e
4/6 155 71 62-80
5/6 97 75 63-87
6/6 16 75 46-100
HCT-CI .04
None 67 82 64-87 1.0
1-2 66 76 62-80 .82 .55-1.22 .33
3þ 129 67 57-78 .67 .47-.94 .02
CD34 dose <.01
<3.5  107 64 58 44-72 1.0
3.5  107 204 77 69-86 1.81 1.29-2.55 <.01
Chronic GVHD
MMF .17
2 g 93 27 17-36 1.0
3 g 175 20 14-26 .69 .41-1.15 .15
Gender .14
Male 163 26 19-33 1.0
Female 105 17 10-25 .41 .28-.84 .01
Female donor to male recipient .93
No 141 22 15-29 1.0
Yes 127 23 15-31 .54 .28-1.04 .07
NRM
MMF .74
2 g 93 15 8-22 1.0
3 g 175 14 9-19 .93 .48-1.81 .83
Disease risk .02
Standard 126 9 4-14 1.0
High 142 19 13-26 2.28 1.13-4.61 .02
ATG .07 e e e
No 182 12 7-16
Yes 86 20 11-28
Relapse
MMF .78
2 g 93 40 29-51 1.0
3 g 175 43 35-51 1.14 .77-1.69 .52
Female donor to male recipient .16
No 141 38 29-46 1.0
Yes 127 46 36-55 1.33 .92-1.92 .13
ATG .05
No 182 47 39-55 1.0
Yes 86 31 20-41 .56 .36-.87 .01
DFS
MMF .88
2 g 93 40 30-50 1.0*
3 g 175 37 30-44 1.05* .77-1.43 .74
CD34 dose .02
<3.5  107 64 29 19-41 1.0*
3.5  107 204 41 34-48 .69* .49-.96 .03
OS
MMF .85
2 g 93 62 52-71 1.0y
3 g 175 61 53-67 1.03y .72-1.47 .87
CD34 dose .03
(Continued on next page)
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Table 3
(continued)
Variable n Univariable Multivariable
Estimate (%) 95% CI P Value RR 95% CI P Value
<3.5  107 64 50 37-61 1.0y
3.5  107 204 65 58-71 .70y .48-1.02 .07
* Denotes relative risk of death/relapse.
y Denotes relative risk of death.
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We compared the clinical outcomes of patients with he-
matological malignancies undergoing RIC dUCB HCT who
received an immunosuppressive regimen that includedeither
MMF 3 g/day or MMF 2 g/day in combinationwith CSA. MMF
dose had no signiﬁcant effect on hematopoietic recovery, risk
of infectious complications, relapse, or mortality, but the
higher dose ofMMFresulted in a signiﬁcantly lower incidence
of grade II to IV acute GVHD. In addition, we observed a
nonstatistically signiﬁcant lower incidence of grade III and IV
acuteGVHDwith the higher dose ofMMF; however, given the
overall low incidence of grade III and IV acute GVHD in UCB
transplantation, a larger patient cohort will be required to
better study this association. This ﬁnding extends our previ-
ous reports showing that MMF 3 g/day not only increases the
proportion of patients achieving therapeuticMPA target AUC,
but it also lowers the risk of acute GVHDwhen adequateMPA
AUC is achieved [13,14]. This observation was recently
reproduced by others as well [12,26]. The Seattle group pre-
viously reported that administration of higher doseMMF had
no effect on the risk of GVHD [10]; however, this group
recently reported that higher therapeuticMPA AUC protected
recipients of adult unrelated donor RIC transplantation from
acute GVHD [12]. Although MPA AUC testing is clinically
available, we used uniform dosing and did not guide MMF
dosing byMPAAUC. In a smaller number of patients, Harnicar
et al. presented data showing a correlation between higher
MPA levels and lower risk of acute GVHD in dUCB HCT with
MMF and CSA-based immunosuppression [26]. Notably, in
our series, the reduction in acuteGVHDwas limited to grade II
and liver involvement, with no effect on severe acute or
chronic GVHD. The data from our group and others demon-
strate that a higher dose MMF results in better exposure to
MPA and reduces acute GVHD, and importantly it does not
compromise engraftment, infection risks, or the antineo-
plastic effects of the HCT. Despite the use of MMF after hap-
loidentical donor transplantation [27,28], we recommendFigure 3. Neutrophil engraftment by MMF dose.caution in extrapolating our MMF data as its effect has not
been yet studied in this setting.
As our study included patients treated before the adoption
of the consensus criteria [16], we used clinical criteria to
differentiate acute GVHD from chronic GVHD [17]. Although
there could have been some additional earlier cases of late-
onset acute and overlap presentations of chronic GVHD
recognized in the2gMMFcohort, the robust18%absolute and
42% RR reduction in the risk of GVHD would be unlikely to
signiﬁcantly change our conclusions. Immunosuppressive
therapy in our study consisted ofMMFandCSA; therefore, the
proposedMMF3 g/day dose examined in this study cannot be
generalized to MMF when used in combination with tacroli-
mus because of underlying pharmacokinetic differences [29].
In our study, patients receiving MMF 3 g/day received
better matched UCB grafts, possibly reﬂecting a larger in-
ventoryofUCBandourability toﬁndbettermatchedgrafts for
our patients in recent years. However, previous reports byour
group and others failed to demonstrate a signiﬁcant impact of
HLAmatchingonGVHDrates afterUCBHCT [7,30]. In contrast,
1 recent study reported a reduction in the risk of severeGVHD
after dUCB HCT for patients with better allele-level HLA
matching of the predominant UCB unit [31]. However, in our
sample, the effect of allele-level typing on the outcomes of
dUCB HCT did not conﬁrm this association [32]. Thus, in the
complexmicroenvironment after dUCBHCT, the effect of HLA
matching on the risk of acute GVHD remains uncertain.
Our ﬁndings that a higher dose of MMF did not affect he-
matopoietic engraftment or infections provide clinically useful
information. Although MMF can cause leukopenia and, there-
fore, could potentially have adverse impact on hematopoietic
recovery, neutrophil engraftment was not impaired by higher
MMF dose, as originally reported by our group [13] and others
[9,10]. The data from Maris et al. showed an improvement on
sustained engraftment from 85% in their historical control
(MMF 15 mg/kg twice daily) to 95% with a higher MMF dose
(MMF 15 mg/kg thrice daily) [10]. The engraftment rate in our
historical controlswas 93% in contrast to 90%with the higher 3
g/day dose of MMF. Thus, even if engraftment were enhanced
by a higher MMF dose, which it was not, it would take a sub-
stantially larger sample size to demonstrate a statistically sig-
niﬁcant improvement from this higher baseline success rate. In
addition,we observedno adverse effect ofMMF3 g/dayon risk
of infections or infection-related death after HCT. In contrast,
Maris et al. found a higher risk of infections early after HCT in
patients receiving a higher MMF dose [10]. Improvements in
supportive care, infectious prophylaxis, and treatment may
explain, at least inpart, the similar infection risk between the 2
MMF dose levels.
Despite the lower rate of acute GVHD in patients receiving
MMF 3 g/day, we observed no differences in NRM between
the MMF dose levels. This was not unexpected because the
effect was largely limited to the risk of grade II GVHD and not
grades III and IV acute GVHD. In a previous study, grade III
Figure 4. Infections by MMF dose.
N. Bejanyan et al. / Biol Blood Marrow Transplant 21 (2015) 926e933932and IV acute GVHD has been associated with higher treat-
ment failure after UCB HCT [3]. Data from McDermott et al.
suggest that identiﬁcation of patients with inadequate MPA
levels and adjusting the dose would also reduce the risk of
severe GVHD and NRM [12]. Although we do not have spe-
ciﬁc data on, for example, gastrointestinal side effects asso-
ciated with a higher MMF dose, myelosuppression as
measured by time to engraftment was a possible surrogate
measure that was not adversely affected by MMF 3 g/day.
Similarly, a higher MMF dose did not affect disease
relapse after HCT. Although the no-ATG group had a higher
incidence of malignancy relapse after transplantation, this
association was expected with omission of ATG in high-risk
disease cases per study protocol. Higher infused total
CD34þ dose was associated with improved neutrophil and
platelet engraftment and lower risk of treatment failure.
However, a higher MMF dose was not associated with
treatment failure or mortality after HCT.
In conclusion, our study supports the use of MMF 3 g/day
in the context of RIC dUCB transplantation. Although phar-
macokinetic monitoring of MPA might be useful for indi-
vidualized MMF dosing, given that MMF 3 g was well
tolerated, the cost beneﬁt of such intervention needs to be
carefully considered. However, if we were to pursue MMF
doses in the higher end of the spectrum of our study (40
mg/kg), we would need to closely monitor pharmacokinetics
and adverse effects, and such a study should only be un-
dertaken in the context of a clinical trial.ACKNOWLEDGMENTS
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